SURPASS-2

What is SURPASS-2?

Tirzepatide against semaglutide 1 mg in type 2 diabetes (Frías et al., NEJM 2021): HbA1c −2.30 points against −1.86, and body weight −11.2 kg against −5.7 kg over 40 weeks.

The first major head-to-head between the two leaders, at a diabetes dose rather than a weight-management one.

Related reading: SURPASS-2: Tirzepatide Against Semaglutide in Diabetes

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where SURPASS-2 comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers